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ABSTRACT
Objective: Plasma brain natriuretic peptide (BNP)
concentrations predict prognosis in patients with
valvular heart disease (VHD), but it is unclear whether
this directly relates to disease severity. We assessed
the relationship between BNP and echocardiographic
measures of disease severity in patients with VHD.
Methods: Plasma BNP concentrations were measured
in patients with normal left ventricular (LV) systolic
function and isolated VHD (mitral regurgitation (MR),
n=33; aortic regurgitation (AR), n=39; aortic stenosis
(AS), n=34; mitral stenosis (MS), n=30), and age-
matched and sex-matched controls (n=39) immediately
prior to exercise stress echocardiography.
Results: Compared with controls, patients with VHD
had elevated plasma BNP concentrations (MR median
35 (IQR 23–52), AR 34 (22–45), AS 31 (22–60), MS
58 (34–90); controls 24 (16–33) pg/mL; p<0.01 for
all). LV end diastolic volume index varied by valve
lesion; (MR (mean 77±14), AR (91±28), AS (50±17),
MS (43±11), controls (52±13) mL/m2; p<0.0001).
There were no associations between LV volume and
BNP. Left atrial (LA) area index varied (MR
(18±4 cm2/m2), AR (12±2), AS (11±3), MS (19±6),
controls (11±2); p<0.0001), but correlated with plasma
BNP concentrations: MR (r=0.42, p=0.02), MS (r=0.86,
p<0.0001), AR (r=0.53, p=0.001), AS (r=0.52,
p=0.002). Higher plasma BNP concentrations were
associated with increased pulmonary artery pressure
and reduced exercise capacity. Despite adverse cardiac
remodelling, 81 (60%) patients had a BNP
concentration within the normal range.
Conclusions: Despite LV remodelling, plasma BNP
concentrations are often normal in patients with VHD.
Conversely, mild elevations of BNP occur with LA
dilatation in the presence of normal LV. Plasma BNP
concentrations should be interpreted with caution
when assessing patients with VHD.
INTRODUCTION
Brain natriuretic peptide (BNP) is a powerful
prognostic marker in patients with a broad
range of cardiac diseases, including acute1
and chronic heart failure,2 3 and postmyocar-
dial infarction.4 Plasma levels of BNP may
KEY QUESTIONS
What is already known about this subject?
▸ It is recognised that plasma brain natriuretic
peptide (BNP) concentrations are elevated in
patients with different valvular heart lesions.
Patients who are symptomatic or have more
severe valve lesions tend to have higher plasma
BNP concentrations. Consequently, for a given
valve lesion, it has been suggested that BNP
levels could be used to screen for significant
valve disease, or identify patients with an
adverse prognosis. Many of these studies were
small and did not include any objective assess-
ment of functional capacity. In addition, no prior
study has systematically compared plasma BNP
concentrations across different valve lesions.
What does this study add?
▸ This study recruited a relatively large number of
patients with valvular heart disease, in order to
assess plasma BNP levels across different valve
lesions. The main findings are that significant
adverse cardiac remodelling can occur in valvu-
lar heart disease despite plasma BNP concentra-
tions that remain within the normal range. In
addition, an elevated BNP was found in a
number of asymptomatic patients, and these
patients performed less well on exercise testing
than those whose plasma BNP concentration
remained within the normal range. Finally,
plasma BNP concentrations in all valve lesions
were associated with markers of left atrial but
not left ventricular size suggesting that left atrial
release of BNP is significant in patients with
valvular heart disease.
How might this impact on clinical practice?
▸ As significant cardiac remodelling can occur
despite plasma BNP concentrations that remain
within the normal range, plasma BNP levels
should be interpreted with caution and not used
as a screening test to detect significant valve
disease. However, despite this, in an apparently
asymptomatic patient, an elevated BNP is pre-
dictive of poor performance on exercise testing,
and this finding should prompt careful reassess-
ment of the patient.
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also increase in patients with valvular heart disease,5–12
particularly in patients with symptoms and more severe
valve lesions. Higher levels of BNP may be associated
with a worse outcome in patients with mitral regurgita-
tion13 and aortic stenosis.14 Patients with valve disease
who have signiﬁcant left ventricular (LV) impairment
often have very high levels of BNP,15 16 but in these
patients the indications for surgery are already clear.
Measurement of BNP may, however, be useful in patients
with heart valve disease and preserved LV systolic func-
tion, especially when symptoms and haemodynamic data
are equivocal.
Previous studies have evaluated the relationship
between plasma BNP concentrations and echocardio-
graphic measures of disease severity, as well as clinical
outcomes for speciﬁc valve lesions including aortic sten-
osis (AS), aortic regurgitation (AR), mitral regurgitation
and mitral stenosis (MS).5 9 17 18 However, each
aortic and mitral valve lesion causes different cardiac
pressure and volume loads, and it is unclear whether
the mechanism of BNP release and clinical implications
of elevated plasma BNP concentrations are dependent
on valve lesion type. These previous studies did not dir-
ectly compare patients with different valve lesions, which
result in different volume and pressure loads on the
heart. The aim of this study was to identify both
common and valve lesion-speciﬁc factors associated with
higher plasma BNP concentrations in patients with pre-
served LV systolic function, who have isolated AS, AR,
mitral regurgitation (MR) or MS, and to assess suitability
of BNP for identifying patients with severe valvular heart
disease (VHD) across different valve lesions.
METHODS
Patients with moderate to severe AS (peak velocity
>3.0 m/s), moderate to severe AR (left ventricular
outﬂow tract (LVOT) width ratio >0.3 and holodiastolic
ﬂow reversal in descending thoracic aorta), moderate to
severe MS (mitral valve area <1.5 cm2), and moderate to
severe or severe MR (effective regurgitant oriﬁce area
>0.3 cm2) were identiﬁed from echocardiogram reports
and outpatient clinics in the Auckland region.19 20 All
patients had normal left ventricular ejection fraction
(LVEF) (AS≥50%, AR >50%, MR≥60%, MS≥50).21
Exclusion criteria included ischaemic heart disease, sig-
niﬁcant renal impairment (creatinine>0.16 mmol/L on
baseline blood tests performed at enrolment), respira-
tory disease, and an inability to walk on a treadmill or a
contraindication to exercise testing. All patients eligible
for inclusion were invited to participate. The patient’s
symptomatic status was assessed according to the
New York Heart Association (NYHA) criteria by a cardi-
ologist blinded to echocardiographic data and peptide
levels at the time of enrolment. Patients who were mildly
symptomatic, or who had equivocal symptoms, were con-
sidered to be NYHA 2 in the analysis. Control subjects
were volunteers from the local community who were age
and sex matched. They were recruited by advertisement
and had no clinical evidence of cardiovascular or
respiratory disease. The study was approved by the
Northern X Ethics Committee, Auckland. The authors
of this manuscript have certiﬁed that they comply with
the Principles of Ethical Publishing.22 The main
outcome was the ability of plasma BNP concentrations to
identify patients with haemodynamically signiﬁcant valve
disease as assessed by exercise stress echocardiography.
Exercise testing
All patients underwent symptom-limited exercise testing
on a motorised treadmill. A standard Bruce protocol was
used for patients with mitral regurgitation. However, it
was noted that there was signiﬁcant clustering of exercise
times at the end of each stage, and this was felt to
adversely affect the objectivity of the determination of
exercise capacity. Consequently for subsequent patients,
the protocol was adjusted so that the speed and/or
incline of the treadmill were increased at 1 min intervals.
The maximum workload at the end of each 3 min stage
remained equivalent to that of the standard Bruce proto-
col. Exercise was stopped for signiﬁcant dyspnoea, chest
discomfort, presyncope, fatigue or at patient request.
Echocardiography
All echocardiograms were performed by experienced
sonographers on cardiac ultrasound scanners (Vivid 7,
General Electric, Vingmed Ultrasound, Norway). All
patients underwent comprehensive examination includ-
ing M-mode, two-dimensional, Doppler and tissue
Doppler echocardiography modiﬁed according to their
underlying valvular lesions consistent with current guide-
lines.20 23 All analyses were performed ofﬂine (Echopac
PC, GE Medical, Milwaukee, Wisconsin, USA) by an
experienced cardiologist blinded to the results of the
patient characteristics and BNP data. All measurements
were averaged from at least three, or in cases of atrial
ﬁbrillation (AF), ﬁve cardiac cycles. The LV end-systolic
and end-diastolic volumes and EF were measured from
the apical four-chamber view using the modiﬁed
Simpson’s single-plane method.24 This method was
chosen to allow comparison with the postexercise
volumes. The left atrial area was measured in the apical
four-chamber view.25
Quantitative and qualitative measures of AS and regur-
gitation severity were made according to American
Society of Echocardiography guidelines.19 20
Quantitative measures of AS severity included peak vel-
ocity, mean pressure drop and aortic valve area.
Assessment of AR severity included the AR jet:LVOT
width ratio, AR pressure half time, peak diastolic and
end-diastolic ﬂow velocities in the descending thoracic
and abdominal aorta.
The severity of MR was assessed by quantitative
Doppler with mitral and aortic stroke volumes,26 and by
the proximal isovelocity surface area method.27 The
stroke volumes obtained from the two methods were
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averaged to give a mean regurgitant volume.11 The
mitral valve area (MVA) was obtained using direct plan-
imetry, pressure half time and continuity methods.28–30
The median MVA from these three methods was used
for analysis. Mean transmitral pressure gradients were
obtained by tracing the continuous wave Doppler signal
across the mitral valve.31
To facilitate estimation of right ventricular systolic
pressure, agitated saline was injected to enhance the tri-
cuspid regurgitation proﬁle.32 The peak pulmonary
artery systolic pressure was derived using the simpliﬁed
Bernouilli equation from the peak tricuspid regurgitant
jet, and added to an estimate of right atrial pressure
obtained from imaging of the inferior vena cava.33 Left
atrial area, left ventricular volumes, valve areas and
effective regurgitant oriﬁce areas were indexed to body
surface area.34
Measurement of natriuretic peptides
Blood samples were obtained from an indwelling intra-
venous catheter after 15 min lying supine, immediately
prior to the baseline echocardiogram. Patients fasted for
2 h prior to the investigations. Blood samples were col-
lected in EDTA tubes, and plasma stored at –80°C and
for measurement of BNP levels at the study end using
established radioimmunoassays.35 The upper limit of the
normal reference range for BNP is 42 pg/mL. To
convert BNP levels expressed in pg/mL to pmol/L,
divide by 3.47.35 36
Statistical analysis
Previous studies have demonstrated a mean plasma BNP
concentration of 22±7 pg/mL in the normal healthy
population.35 A minimum sample size of 30 in each
valve subgroup was required to detect a 20% increase in
plasma BNP concentrations compared to controls
(power of 80% and α=0.01). Categorical data were pre-
sented as frequency and percentage, and continuous
data were presented as mean±SD, or median and IQR.
BNP underwent natural log transformation in analyses
due to its right skewed distributions unless speciﬁed,
and was reported as median and interquartile range.
Comparison of all valves versus the control group and
valve subgroups, was performed using the χ2 or Fisher’s
exact tests for categorical data where appropriate. For
continuous variables, two independent sample Student t
test or non-parametric Mann–Whitney U test was used
where appropriate, for comparing all-valve versus
control groups. For comparison between subgroups of
valves, one-way analysis of variance was performed fol-
lowed by the Dunnett’s test, to compare each valve sub-
group with control subjects. The Kruskal–Wallis test was
used when the continuous data was not normally distrib-
uted. Pearson correlation coefﬁcients were reported for
linear associations. All p values reported were two-tailed,
and a p value <0.05 was considered signiﬁcant. Data
were analysed using SAS statistical package, V.9.1.3 (SAS
Institute, Cary, North Carolina, USA).
RESULTS
All patients who agreed to participate completed all
aspects of the study. One hundred and seventy-ﬁve sub-
jects with isolated MR (n=33), AR (n=39), AS (n=34)
and MS (n=30) or normal valves (n=39) were studied.
Plasma BNP concentrations and exercise treadmill data
were available for all patients. Plasma BNP concentra-
tions (median, interquartile range) were elevated in all
valve lesions compared with controls (MR (35 pg/mL,
23–52), AR (34 pg/mL, 22–45), AS (31 pg/mL, 22–60),
MS (58 pg/mL, 34–90), control (24 pg/mL, 16–33);
p<0.01 for all).
Patients with AS were predominantly male, whereas
patients with MS were predominantly female (table 1). In
keeping with the higher proportion of degenerative valve
disease, patients with AS were generally older than those
with other valve lesions. Patients with mitral valve disease
had a higher plasma BNP concentration than those with
aortic valve disease (46 (29–73) vs 32 (22–49) pg/mL,
p=0.012). For each given valve lesion, patients with MS
had the highest plasma concentration of BNP. This
remained the case if patients with AF were excluded from
the analysis (BNP in MS with sinus rhythm 55 (30–73) vs
other valve lesions 34 (22–52) pg/mL; p=0.02).
The relative use of cardiac medication differed
between valve groups. Patients with AR were the most
likely to be taking medication, with 64% of patients
taking an ACE inhibitors inhibitor. Forty-three per cent
of patients with MS were taking a loop diuretic (at a
dose of 40 mg furosemide or less), and 32% of patients
with AS were taking a betablocker. Patients with AS who
were not taking a betablocker had lower plasma BNP
concentrations than those who were (26 (20,41) vs 42
(34,63); p=0.03). There was no other statistically signiﬁ-
cant difference in plasma BNP concentrations between
patients who were taking medication compared to those
who were not in any other valve subgroup.
Adverse cardiac remodelling
Although all subjects had normal LVEF, LV end diastolic
volume index (LVEDVI) varied considerably across
patients and by valve lesion (MR 77±14, AR 91±28, AS
50±17, MS 43±11 and controls 52±13 mL/m2; p<0.0001).
For each valvular lesion, patients were divided into two
groups depending on whether the plasma BNP concen-
tration was within the normal range (≤42 pg/mL) or
elevated. The relative numbers of patients with elevated
BNP in each group are shown in table 2. Even when
plasma BNP concentration remained within the normal
range, those with regurgitant valve lesions had signiﬁ-
cant LV dilatation compared to controls: (LVEDVI in
MR 78±14, AR 88±27 and controls 52±12 mL/m2;
p=<0.0001). There was no association between any
resting measure of LV function and plasma BNP concen-
tration (table 3).
LA area index (LAAI) was greater in patients with
mitral compared to aortic valve disease: (MR 17±4, MS
19±6, AR 11±2, AS 11±2) and controls (11±2 cm2/m2;
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Table 1 Baseline characteristics, baseline echocardiographic and exercise data
Controls MR MS AS AR All valves p Value* p Value†
Number of subjects 39 33 30 34 39 136
Age (years) 55±15 53±16 49±14 67±9‡ 42±14‡ 53±16 0.404 <0.001
Female, n (%) 16 (41) 15 (45) 28 (93) 4 (12) 6 (15) 53 (39) 0.817 <0.001
Body mass index (kg/m2) 25.8±3.5 27.7±5.0 28.6±5.8 28.9±4.5‡ 28.8±4.7‡ 28.5±4.9 0.001 0.023
Atrial fibrillation, n (%) 0 (0) 0 (0) 8 (27) 0 (0) 0 (0) 8 (6) 0.202 <0.001
Symptomatic, n (%) 1 (3) 17 (52) 14 (47) 17 (50) 7 (18) 55 (40) <0.001 <0.001
Medication, n (%)
Loop diuretic 0 (0) 4 (12) 13 (43) 5 (15) 2 (5) 24 (18) 0.003 <0.001
ACE inhibitor 0 (0) 6 (18) 4 (13) 4 (12) 25 (64) 39 (29) <0.001 <0.001
Beta blocker 0 (0) 6 (18) 4 (13) 11 (32) 2 (5) 23 (17) 0.006 <0.001
BNP (pg/mL) 24 (16–33) 35 (23–52) 58 (34–90) 31 (22–60) 34 (22–45) 36 (24–62) <0.001 <0.001
Left atrial area index 10.5±1.9 17.5±4.4‡ 19.3±5.9‡ 11.5±2.5 10.8±2.0 14.5±5.4 <0.001 <0.001
LVEDVI (mL/m2) 52.3±12.7 76.6±14.0‡ 43.4±11.2 49.6±16.5 91.3±28.4‡ 66.9±27.6 0.003 <0.001
LVESVI (mL/m2) 19.0±7.1 26.9±6.5‡ 16.5±5.9 20.8±12.3 33.9±14.1‡ 25.1±12.4 0.005 <0.001
LVEF (%) 64.5±7.6 64.6±6.7 62.4±7.3 61.9±7.0 63.7±6.3 63.2±6.8 0.320 0.380
PA pressure (mm Hg) 24±4 37±13‡ 36±12‡ 32±7‡ 28±7 33±10 <0.001 <0.001
Peak heart rate (bpm) 153±16 153±21 148±24 129±20‡ 133±19‡ 140±23 0.0003 <0.001
Exercise capacity (METS) 12.5±3.1 9.1±2.7‡ 6.3±2.6‡ 9.1±3.2‡ 10.9±3.4 9.0±3.4 <0.001 <0.001
Peak systolic BP (mm Hg) 169±23 163±30 132±23‡ 159±22 188±24‡ 163±32 0.183 <0.001
*p Value relates to all-valves patients compared with controls.
†p Value for comparison between subgroups.
‡Comparison significant at the 0.05 level between each valve group versus controls.
Results are Mean±SD except BNP which is median (IQR).
BNP, brain natriuretic peptide; BP, blood pressure; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index;
METS, metabolic equivalents; PA, pulmonary artery.
4
Sharm
a
V,Stew
artRA,Lee
M
,etal.Open
Heart2016;3:e000184.doi:10.1136/openhrt-2014-000184
O
p
e
n
H
e
a
rt
group.bmj.com
 o
n
 July 26, 2016 - Published by 
http://openheart.bmj.com/
D
ow
nloaded from
 
Table 2 Measures of cardiac remodelling, valve severity and exercise capacity for each valve lesion stratified by BNP
Controls
Aortic
stenosis
Mitral
stenosis
Aortic
regurgitation
Mitral
regurgitation
Number of subjects Normal BNP 34 24 10 29 21
High BNP 5 10 20 10 12
Total 39 34 30 29 33
NYHA class 2, n (%) Normal BNP 1 (2.9) 8 (33.3) 3 (33.3) 3 (10.3) 7 (33.3)
High BNP 0 (0) 7 (70.0) 11 (55.0) 2 (20.0) 8 (66.7)
p Value 1.00 0.20 0.26 0.03 0.09
Severe valve disease, n (%) Normal BNP – 3 (13) 1 (10) 15 (52) 15 (71)
High BNP – 5 (50) 4 (20) 9 (90) 6 (50)
p Value – 0.03 0.64 0.06 0.27
LV end-diastolic volume index (mL/m2) Normal BNP 52±12 50±17 45±7 88±27 78±14
High BNP 53±16 48±17 42±13 100±31 75±14
p Value 0.96 0.73 0.50 0.20 0.59
LV end-systolic volume index (mL/m2) Normal BNP 19±7 19±9 16±5 32±13 28±6
High BNP 19±60.89 24±190.95 16±60.91 39±170.25 26±70.81
p Value
LV ejection fraction (%) Normal BNP 64±8 61±7 63±8 64±6 64±7
High BNP 65±9 63±6 62±7 63±6 66±7
p Value 0.90 0.47 0.57 0.54 0.57
LA area index (cm2/m2) Normal BNP 10±2 11±2 15±2 10±2 17±4
High BNP 11±3 13±3 21±6 12±2 18±5
p Value 0.69 0.008 0.0005 0.07 0.47
Pulmonary artery pressure (mm Hg) Normal BNP 24±4 31±6 34±16 27±6 32±7
High BNP 25±6 35±7 36±9 32±6 47±16
p Value 0.77 0.16 0.14 0.06 0.008
Valve area index/EROA index (cm2/m2) Normal BNP – 0.51±0.13 0.75±0.15 0.10±0.07 0.34±0.16
High BNP – 0.41±0.09 0.62±0.14 0.16±0.08 0.32±0.16
p Value 0.04 0.03 0.02 0.72
Exercise capacity (METS), Normal BNP 12±3 10±3 8±3 11±4 10±2
High BNP 14±3 7±2 5±2 11±3 7±2
pValue 0.22 0.003 0.02 0.65 0.001
All data is mean±SD unless otherwise stated. p Values relate to comparison of normal versus raised BNP groups.
BNP, brain natriuretic peptide; EROA, effective regurgitant orifice area; LA, left atrium; LV, left ventricle; METS, metabolic equivalents; NYHA,
New York Heart Association.
Table 3 Associations between BNP, echocardiographic variables and exercise capacity
Controls r
(p)
Aortic
stenosis r
(p)
Mitral
stenosis r (p)
Aortic
regurgitation r
(p)
Mitral
regurgitation r
(p) All valves r (p)
LV end-diastolic volume
index (mL/m2)
0.22 (0.20) 0.02 (0.93) −0.24 (0.20) 0.16 (0.34) −0.02 (0.28) −0.01 (0.85)
LV end-systolic volume
index (mL/m2)
0.13 (0.43) 0.10 (0.59) −0.06 (0.74) 0.19 (0.24) −0.19 (0.31) 0.01 (0.86)
Left atrial area index
(cm2/m2)
0.10 (0.57) 0.52 (0.002) 0.86 (<0.0001) 0.53 (0.001) 0.42 (0.02) 0.57 (<0.0001)
Pulmonary artery
pressure (mm Hg)
0.29 (0.08) 0.40 (0.037) 0.47 (0.008) 0.39 (0.02) 0.53 (0.002) 0.36 (<0.0001)
Valve area/EROA index
(cm2/m2)
– −0.28 (0.10) −0.23 (0.21) 0.22 (0.18) −0.05 (0.79) -
Exercise capacity
(METS)
0.23 (0.16) −0.44 (0.009) −0.56 (0.001) −0.11 (0.52) −0.53 (0.001) −0.38 (<0.0001)
Pearson’s correlation used for analysis.
BNP, brain natriuretic peptide; EROA, effective regurgitant orifice area; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left
ventricular end-systolic volume index; METS, metabolic equivalents.
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p<0.0001). Patients with plasma BNP concentrations
>42 pg/mL had a greater LAAI compared to those with
a normal BNP in MS (21±6 vs 15±2; p<0.001) and in AS
(13±3 vs 11±2; p<0.01). Despite no association with
markers of LV size, there was a consistent correlation
with LAAI across all valve lesions: MR (r=0.42, p=0.02),
MS (r=0.86, p<0.0001), AR (r=0.53, p=0.001), AS
(r=0.52, p=0.002), all valves (r=0.57, p<0.0001). An
increase in plasma BNP concentration was also asso-
ciated with a higher pulmonary artery pressure in all
valve lesions.
Exercise capacity and functional status
Across all valve lesions, 55 (40%) patients were symptom-
atic and were more likely to have a raised plasma BNP
concentration than those who remained asymptomatic
(49 (32–79) vs 31 (22–44) pg/mL; p<0.001). Patients
who were symptomatic had higher pulmonary artery
pressures (38±12 vs 29±8 mm Hg; p<0.001), larger LAAI
(16±6 vs 14±5 cm2/m2; p=0.02), and lower exercise cap-
acity (7.1±2.4 vs 10.4±3.4 metabolic equivalents (METS);
p<0.001) than asymptomatic subjects. However, this
ﬁnding was not consistent across all valve subgroups
and, in particular, although asymptomatic patients with
MS and AR had slightly higher exercise capacity than
those with mild symptoms, this was not statistically sig-
niﬁcant (table 4). Patients with an elevated BNP per-
formed less well on the treadmill than those with a
normal BNP (10.1±3.1 vs 7.2±3.1 METS, p<0.0001). This
ﬁnding was consistent and statistically signiﬁcant for all
valve subgroups except for those with AR (table 2).
However, the patients with poor exercise capacity iden-
tiﬁed by NYHA class, and those by an elevated plasma
BNP concentration, were not identical. Of the 81
patients in NYHA class 1, 20 patients had an elevated
BNP. These patients performed less well on the treadmill
than asymptomatic patients in whom BNP remained
within the normal range (10.9±3.1 vs 8.7±3.8 METS,
p=0.01).
DISCUSSSION
This study evaluated associations between the plasma
BNP concentrations and echocardiographic measures of
LV and LA remodelling in patients with moderate to
severe aortic and mitral valve disease. Patients with
Table 4 Characteristics of asymptomatic versus symptomatic patients (mean±SD unless otherwise stated)
Controls
Aortic
stenosis
Mitral
stenosis
Aortic
regurgitation
Mitral
regurgitation
Number of subjects NYHA 1 39 17 16 32 16
NYHA 2 17 14 7 17
Total 39 34 30 39 33
BNP (pg/mL) NYHA 1 26.8±13.0 33.7±19.3 60.2±45.9 40.9±37.7 33.6±19.4
NYHA 2 – 45.0±24.8 86.1±50.4 74.2±75.9 52.3±29.7
p Value 0.19 0.08 0.10 0.04
Severe valve disease, n (%) NYHA 1 – 2 (12) 1 (6) 19 (58) 13 (81)
NYHA 2 – 6 (35) 4 (29) 5 (71) 8 (47)
p Value 0.22 0.16 0.69 0.04
LV end-diastolic volume index (mL/m2) NYHA 1 52.3±12.7 52.8±14.4 46.9±9.6 90.3±28.6 80.5±11.2
NYHA 2 – 46.6±18.1 39.4±11.8 95.7±29.5 72.9±15.6
p Value 0.28 0.07 0.57 0.12
LV end-systolic volume index (mL/m2) NYHA 1 19.0±7.1 18.7±7.6 17.9±6.1 33.3±13.7 28.3±6.4
NYHA 2 – 22.8±15.4 14.9±5.4 36.7±16.8 25.6±6.5
p Value 0.61 0.18 0.50 0.61
LV ejection fraction (%) NYHA 1 65±8 63±8 62±9 64±6.2 65±7
NYHA 2 – 61±6 63±4 63±7 65±6
p Value 0.32 0.86 0.80 0.96
LA area index (cm2/m2) NYHA 1 10.6±1.9 11.5±2.5 18.2±6.0 10.6±2.0 17.4±3.9
NYHA 2 – 11.4±2.6 20.5±5.9 11.8±2.0 17.6±5.0
p Value 0.90 0.16 0.14 0.73
Pulmonary artery pressure (mm Hg) NYHA 1 25±4 30±7 32±14 28±6 32±6
NYHA 2 – 35±6 40±8 31±9 42±16
p Value 0.06 0.01 0.19 0.03
Valve area index/EROA index (cm2/m2) NYHA 1 – 0.51±0.09 0.71±0.15 0.11±0.07 0.38±0.16
NYHA 2 – 0.45±0.14 0.62±0.16 0.16±0.07 0.29±0.15
p Value 0.15 0.13 0.06 0.10
Exercise capacity (METS) NYHA 1 12.6±3.1 10.9±2.8 7.0±3.0 11.3±3.6 11.1±1.6
NYHA 2 – 7.4±2.5 5.5±2.0 9.4±1.9 7.2±2.1
p Value 0.003 0.19 0.26 <0.0001
BNP, brain natriuretic peptide; EROA, effective regurgitant orifice area; LA, left atrium; LV, left ventricle; NYHA, New York Heart Association.
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impaired LVEF were excluded, so that the impact of
factors other than LV systolic function could be evalu-
ated. There were several clinically relevant observations.
First, while there was a wide range of LV remodelling
across different valve lesions, there was no correlation
between the plasma BNP concentration and LV end sys-
tolic or end diastolic volumes for any valve lesion. This
implies that in VHD patients with normal EF, compensa-
tory LV remodelling is not associated with an increase in
plasma BNP concentration. Second, the plasma BNP
concentration correlated with LA size in all valve lesions.
Third, plasma BNP concentrations were higher in sub-
jects with mitral compared to aortic valve disease, and
highest in patients with mitral stenosis, in which setting
there is no increase in LV wall stretch or pressure load.
BNP also increased with higher pulmonary artery pres-
sures. In these patients, the elevation in pulmonary
artery pressure was likely to be secondary to an increase
in LA ﬁlling pressure. These observations are consistent
with BNP release from the LA in response to an increase
in volume and wall stretch. This hypothesis is supported
by evidence for synthesis of BNP by atrial myocytes in
response to chronic increases in wall stress,37 and costo-
rage of BNP with ANP in atrial granules.38
In aortic valve disease, plasma BNP concentrations
increased with relatively small increases in LA volume. It
is possible that LA dilatation in aortic valve disease
reﬂects subtle LV systolic or diastolic dysfunction.
However, assessment of diastolic function, particularly in
patients with mitral valve disease is not well validated,
and comparison across valve lesions is not possible. In
subjects with mitral valve disease, small increases in LA
volume were often not associated with higher plasma
BNP concentrations, but more marked LA enlargement
usually was. Some patients with mitral stenosis were in
AF, which is known to be associated with higher plasma
BNP concentrations.39 40 The number of patients with
AF in this study was too small to allow a reliable analysis
of the relationship between AF and BNP.
Higher plasma BNP concentration was associated with
pulmonary hypertension in all valve subgroups. In add-
ition, higher BNP was associated with reduced exercise
capacity in all valve lesions except for AR. Symptomatic
patients with any valve lesion were more likely to have
an elevated pulmonary artery pressure or a decreased
exercise capacity. As this elevated pulmonary pressure
and decreased exercise capacity are the objective corre-
lates of symptomatic status, this is not surprising.
However, there was considerable overlap in the objective
parameters between symptomatic and asymptomatic
patients consistent with the known difﬁculties in asses-
sing cardiac symptoms particularly in the early stages of
decompensation.41 Furthermore, although both symp-
tomatic patients and those with elevated plasma BNP
concentrations tended to have objective evidence of
exercise limitation or echocardiographic features of
more advanced valve disease, the patients identiﬁed
were not identical. This suggests that plasma BNP
concentrations may offer additional information in asses-
sing the haemodynamic consequences of valve lesions in
patients with AS, MS and MR. We did not ﬁnd similar
associations between BNP and exercise capacity in
patients with AR. The reason for the lack of a statistically
signiﬁcant association in the AR cohort is uncertain.
Clinical implications
In this study, most patients with severe valve disease had
a plasma BNP concentration of <100 pg/mL: a value
below which cardiac failure is considered unlikely in
patients presenting with dyspnoea.42 Patients with valve
disease and a preserved LVEF may therefore have clinic-
ally important symptoms and pulmonary hypertension
with a relatively modest increase in BNP. Conversely, in
patients with other reasons for an elevated BNP, measur-
ing plasma BNP concentration to assess valve status may
not be helpful. In this study, patients with other known
causes of an elevated BNP were excluded.
Previous studies which evaluate outcomes in patients
with mitral regurgitation13 and AS14 suggest that an ele-
vated BNP may identify patients who have a higher risk
of adverse events. There is known difﬁculty in evaluating
symptoms in some patients,41 and a signiﬁcant number
of asymptomatic patients in this study had an elevated
plasma BNP concentration. These patients had a lower
exercise capacity than those in whom the BNP remained
within the normal range. Consequently, elevated plasma
BNP concentrations in apparently asymptomatic patients
should lead to a more careful assessment regardless of
the type of valve lesion.
Study limitations
The proportion of asymptomatic and symptomatic
patients in each valve group differed, but except in the
AR subgroup, at least half the patients in each valve type
had mild or equivocal symptoms. The small number of
symptomatic patients in the AR subgroup may partly
explain the lack of associations between BNP and exer-
cise capacity in this group. In the AS subgroup, only
asymptomatic patients and those patients with equivocal
symptoms underwent exercise testing, and in the other
subgroups, patients had, at most, mild symptoms, as
those with contraindications to exercise testing were
excluded from the study. In particular, patients with
severe AS with symptoms of angina were excluded from
the study. This selection of predominantly asymptomatic
and mildly symptomatic patients may be responsible for
the relatively modest rise in plasma BNP concentration
in this cohort. However, in clinical practice, patients with
signiﬁcant valve disease who have clear symptoms,
usually have a class 1 indication for surgery or valve
intervention according to current guidelines.21 43
Consequently, the measurement of BNP in these
patients is unlikely to be helpful. A further limitation is
that although the overall number of patients within this
study is modest, the number of patients within each
valve group is relatively small. This limits the power of
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further subgroup analysis or comparison against other
markers of valve severity within each subgroup.
Furthermore, although valve severity was graded accord-
ing to the American Society of Echocardiography/
European Society of Echocardiography guidelines,23 the
grading of severity, particularly between regurgitant and
stenotic lesions differs considerably, and hence, is not
directly comparable.
CONCLUSION
In patients with isolated heart valve disease and a pre-
served EF, signiﬁcant cardiac remodelling can occur
while BNP remains within the normal range. However,
BNP increases with greater left atrial size and pulmonary
artery pressure in all valve lesions. Consequently, plasma
BNP concentrations cannot reliably identify patients
with signiﬁcant valve disease, and therefore, should be
interpreted with caution in these patients. However, ele-
vated BNP levels were associated with poor exercise cap-
acity, and therefore, a raised BNP in an apparently
asymptomatic patient with stable valve disease should
prompt further assessment.
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